BRIEF-Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research

Reuters2023-04-06

April 6 (Reuters) - Magenta Therapeutics Inc :

* MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED INTO SUBLEASE TERMINATION, RELEASE AGREEMENT WITH NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH

* MAGENTA THERAPEUTICS INC - IN EXCHANGE FOR EARLY TERMINATION OF SUBLEASE AGREED TO MAKE ONE-TIME TERMINATION PAYMENT TO NOVARTIS OF $14.8 MILLION

* MAGENTA THERAPEUTICS - POST TERMINATION DATE, CO'S PRINCIPAL EXECUTIVE OFFICES WILL BE LOCATED AT 300 TECHNOLOGY SQUARE IN CAMBRIDGE, MASSACHUSETTS

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2325230332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-06 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2325230332","market":"us","top_or_hot":-1,"title":"BRIEF-Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research","media":"Reuters","content":"<html><body><p>April 6 (Reuters) - Magenta Therapeutics Inc   :</p><p>   * MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED INTO SUBLEASE TERMINATION, RELEASE AGREEMENT WITH NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH</p><p>   * MAGENTA THERAPEUTICS INC - IN EXCHANGE FOR EARLY TERMINATION OF SUBLEASE AGREED TO MAKE ONE-TIME TERMINATION PAYMENT TO NOVARTIS OF $14.8 MILLION</p><p>   * MAGENTA THERAPEUTICS - POST TERMINATION DATE, CO'S PRINCIPAL EXECUTIVE OFFICES WILL BE LOCATED AT 300 TECHNOLOGY SQUARE IN CAMBRIDGE, MASSACHUSETTS</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-06 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 6 (Reuters) - Magenta Therapeutics Inc   :   * MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED INTO SUBLEASE TERMINATION, RELEASE AGREEMENT WITH NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2325230332","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2325230332","pubTimestamp":1680784725,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 6 (Reuters) - Magenta Therapeutics Inc   :   * MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LHDX":"Lucira Health, Inc.","BK4007":"制药","BK4023":"应用软件","BK4196":"保健护理服务","ONTF":"ON24, Inc.","SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","APR":"Apria, Inc.","CGEM":"Cullinan Therapeutics","BK4082":"医疗保健设备"},"translate_title":"简介——Magenta Therapeutics——3月31日，Co与诺华生物医学研究所签订了转租终止、解除协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTA":0.9,"APR":0.8,"CGEM":0.8,"LABP":0.8,"LHDX":0.8,"ONTF":0.8,"SANA":0.8},"content_text":"April 6 (Reuters) - Magenta Therapeutics Inc   :   * MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED INTO SUBLEASE TERMINATION, RELEASE AGREEMENT WITH NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   * MAGENTA THERAPEUTICS INC - IN EXCHANGE FOR EARLY TERMINATION OF SUBLEASE AGREED TO MAKE ONE-TIME TERMINATION PAYMENT TO NOVARTIS OF $14.8 MILLION   * MAGENTA THERAPEUTICS - POST TERMINATION DATE, CO'S PRINCIPAL EXECUTIVE OFFICES WILL BE LOCATED AT 300 TECHNOLOGY SQUARE IN CAMBRIDGE, MASSACHUSETTSFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2325230332"}